<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-r-chp-cd5-dlbcl-xu-pf980">
    <meta name="study:title" content="PF980 - Efficacy of Pola-R-CHP in 1L CD5-Positive DLBCL">
    <meta name="study:fileName" content="Abstracts/POLA-R-CHP-CD5-DLBCL-XU-PF980.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone,Chemotherapy,CIT,Pola-R-CHP,R-CHOP,CAR-T cell therapy,Bispecific antibodies">

    <title>PF980: Pola-R-CHP in 1L CD5+ DLBCL (Xu) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF980 - Pola-R-CHP in 1L CD5-Positive DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>N=27 1L CD5+ DLBCL (Pola-R-CHP) vs matched R-CHOP. Aim: Evaluate Pola-R-CHP efficacy.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M12 2.25c-2.362 0-4.474.924-6.04 2.446a.75.75 0 001.06 1.06A7.501 7.501 0 0112 3.75c2.362 0 4.474.924 6.04 2.446a.75.75 0 101.06-1.06A8.963 8.963 0 0012 2.25zM3.696 7.54a.75.75 0 00-1.06 1.06A8.963 8.963 0 0012 21.75a8.963 8.963 0 009.364-13.15.75.75 0 10-1.06-1.06A7.501 7.501 0 0112 20.25a7.501 7.501 0 01-8.304-12.71zm5.158 7.814a.75.75 0 00-1.061-1.06L6 16.108V13.5a.75.75 0 00-1.5 0v4.5a.75.75 0 00.75.75h4.5a.75.75 0 000-1.5H7.892l1.962-1.963zm6.392-3.188a.75.75 0 00-1.06 1.061L16.108 15H13.5a.75.75 0 000 1.5h4.5a.75.75 0 00.75-.75v-4.5a.75.75 0 00-1.5 0v2.108l-1.962-1.962z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention & Method</h4>
                    <p>Pola-R-CHP vs R-CHOP. Retrospective, matched comparison.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (EOT CRR & PFS)</h4>
                    <p>EOT CRR: Pola-R-CHP <span class="highlight-value">77.8%</span> vs R-CHOP 69.1% (NS). 12m PFS: 85.2% vs 78.1% (NS).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Pola-R-CHP: G3/4 AEs 33.3%. Rapid response, acceptable safety. Longer F/U needed.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF980 - Efficacy of Pola-R-CHP in previously untreated CD5-positive diffuse large B-cell lymphoma</h1>
            <p class="abstract-sub-header">Junqing Xu, Jingrui Sui, Lijie Yan, Peiqi Zhao, Xia Zhao, Xiaofeng Luo, xiangyan Feng, Yuanfeng Zhang, Kaimin Li</p>
            <p class="abstract-meta-info mt-2">EHA2025 Congress | Abstract #PF980 | Poster Presentation | Session: Aggressive Non-Hodgkin lymphoma - Clinical</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CD5-positive diffuse large B-cell lymphoma (DLBCL) is a high-risk subtype with a poor prognosis.</li>
                        <li>In April 2023, Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) was approved in China for the first-line (1L) treatment of DLBCL.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">This study aimed to evaluate the efficacy of Pola-R-CHP as a first-line therapy for CD5-positive DLBCL.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective enrollment of previously untreated CD5-positive DLBCL patients from April 2023 to May 2024 across four institutions.</li>
                        <li>A matched comparison was conducted between Pola-R-CHP and R-CHOP using a DLBCL database from the investigators' institute, covering January 2017 to January 2024.</li>
                        <li>Treatment efficacy assessed via PET/CT scans after 3 cycles (interim) and 6 cycles of R-chemo plus 2 cycles of R (end of treatment - EOT).</li>
                        <li>Statistical tests: Chi-square test and Log-rank test for response rates and progression-free survival (PFS).</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Pola-R-CHP vs R-CHOP in 1L CD5+ DLBCL (Retrospective Matched)</h3>
                        <div class="schema-enrollment">
                            <strong>Previously Untreated CD5+ DLBCL Patients</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 48%;">
                                <strong>Pola-R-CHP Group (N=27)</strong>
                                <span>(Enrolled Apr 2023 - May 2024)</span>
                            </div>
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-orange-bg);">
                                <strong>R-CHOP Group (N=56/55)</strong>
                                <span>(Matched from Database Jan 2017 - Jan 2024)</span>
                            </div>
                        </div>
                         <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Interim PET/CT (after 3 cycles)</span>
                           <span>EOT PET/CT (after 6 cycles R-chemo + 2R)</span>
                           <span>Endpoints: ORR, CRR, PFS, OS, Safety</span>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (Pola-R-CHP Group, N=27)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (IQR)</td><td>64 (50-70)</td></tr>
                                <tr><td>Female, n (%)</td><td>13 (48.1%)</td></tr>
                                <tr><td>Ann Arbor Stage III, n (%)</td><td>8 (29.6%)</td></tr>
                                <tr><td>Ann Arbor Stage IV, n (%)</td><td>12 (44.4%)</td></tr>
                                <tr><td>IPI Score ≥3, n (%)</td><td>15 (55.6%)</td></tr>
                                <tr><td>Extranodal Involvements ≥2, n (%)</td><td>19 (70.4%)</td></tr>
                                <tr><td>Elevated LDH, n (%)</td><td>19 (70.4%)</td></tr>
                                <tr><td>Elevated β2-microglobulin, n (%)</td><td>17 (63.0%)</td></tr>
                                <tr><td>Non-GCB (Hans), n (%)</td><td>~21-22 (~80%)</td></tr>
                                <tr><td>Double-Expressor Lymphoma, n (%)</td><td>9 (33.3%)</td></tr>
                            </tbody>
                        </table>
                        <p class="footnote-text mt-1">Baseline characteristics were well-balanced with the R-CHOP group.</p>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results</h2>
                    <p class="text-sm mb-2">All patients completed treatment and underwent PET-CT assessments. Median follow-up for Pola-R-CHP group was 11.7 months.</p>
                    <div class="table-container">
                        <h3 class="sub-section-title text-center">Response Rates: Pola-R-CHP vs R-CHOP</h3>
                        <table>
                            <thead>
                                <tr><th>Timepoint</th><th>Response</th><th>Pola-R-CHP (N=27)</th><th>R-CHOP (N=56/55*)</th><th>P-value</th></tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td rowspan="2">After 3 Cycles (Interim)</td>
                                    <td>ORR</td>
                                    <td>100% (27/27)</td>
                                    <td>85.7% (48/56)</td>
                                    <td rowspan="2">NS</td>
                                </tr>
                                <tr>
                                    <td>CRR</td>
                                    <td>77.8% (21/27)</td>
                                    <td>55.4% (31/56)</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">End of Treatment (EOT)</td>
                                    <td>ORR</td>
                                    <td>92.6% (25/27)</td>
                                    <td>85.5% (47/55*)</td>
                                    <td rowspan="2">NS</td>
                                </tr>
                                <tr>
                                    <td>CRR</td>
                                    <td>77.8% (21/27)</td>
                                    <td>69.1% (38/55*)</td>
                                </tr>
                            </tbody>
                        </table>
                        <p class="text-xs mt-1 footnote-text">*N=55 for R-CHOP EOT response.</p>
                    </div>
                     <div class="chart-container my-4">
                        <svg id="cd5DlbclResponseChart" width="450" height="320"></svg>
                        <div id="cd5DlbclResponseLegend" class="legend"></div>
                    </div>

                    <h3 class="sub-section-title mt-4">Survival Outcomes</h3>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median PFS and OS in the Pola-R-CHP group were not reached.</li>
                        <li>6-month PFS: Pola-R-CHP 96.3% vs R-CHOP 87.7% (NS).</li>
                        <li>12-month PFS: Pola-R-CHP 85.2% vs R-CHOP 78.1% (NS).</li>
                    </ul>
                    <div class="km-plot-container text-center mt-4">
                        <img id="swimmerPlotImage" src="image_7140f6.jpg" alt="Figure 1: Swimmer plot of patient outcomes in the Pola-R-CHP group" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=Swimmer+Plot+Not+Available';">
                        <p class="text-xs meta-info mt-1">Figure 1: Swimmer plot of patient outcomes in the Pola-R-CHP group (representative image based on abstract description "Assets/AAAFigure1.png"). Click to enlarge.</p>
                    </div>
                     <div id="swimmerPlotLightbox" class="lightbox">
                        <span class="lightbox-close" id="closeSwimmerPlotLightbox">&times;</span>
                        <img class="lightbox-content" id="swimmerPlotLightboxImage">
                        <div class="lightbox-caption" id="swimmerPlotLightboxCaption"></div>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (Pola-R-CHP Group, N=27)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Grade 3 and 4 adverse events (AEs) reported in 9 of 27 (33.3%) patients.</li>
                        <li>Most common Grade 3/4 AE: Neutropenia.</li>
                        <li>Other side effects: Peripheral neuropathy and thrombocytopenia.</li>
                        <li>Two patients experienced fatal disease progression during the study despite subsequent CAR-T cell therapy and CD20xCD3 bispecific antibody treatment.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>CD5-positive DLBCL patients exhibited rapid responses to Pola-R-CHP.</li>
                <li>The Pola-R-CHP treatment demonstrated an acceptable safety profile in this high-risk population.</li>
                <li>Long-term progression-free survival benefits are anticipated with Pola-R-CHP in CD5-positive DLBCL, although extended follow-up is necessary to confirm these findings.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>1L, First-Line; AE, Adverse Event; CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CHP, Cyclophosphamide, Doxorubicin, Prednisone; CI, Confidence Interval; CIT, Chemoimmunotherapy; CRR, Complete Response Rate; DLBCL, Diffuse Large B-Cell Lymphoma; EOT, End of Treatment; F/U, Follow-up; GCB, Germinal Center B-cell like; IPI, International Prognostic Index; IQR, Interquartile Range; LDH, Lactic Dehydrogenase; NS, Not Significant; ORR, Overall Response Rate; OS, Overall Survival; PET/CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; Pola, Polatuzumab vedotin; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Xu J, Sui J, Yan L, et al. Efficacy of Pola-R-CHP in previously untreated CD5-positive diffuse large B-cell lymphoma. Abstract #PF980 presented at the European Hematology Association (EHA) Congress. June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA2025 Congress | Abstract #PF980 | Abstract Release: 05/14/25 | Presentation: June 13, 2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
    <script>
        // Lightbox JavaScript for Swimmer Plot
        document.addEventListener('DOMContentLoaded', function() {
            const lightbox = document.getElementById('swimmerPlotLightbox');
            const lightboxImg = document.getElementById('swimmerPlotLightboxImage');
            const lightboxCaption = document.getElementById('swimmerPlotLightboxCaption');
            const thumbnail = document.getElementById('swimmerPlotImage');
            const closeBtn = document.getElementById('closeSwimmerPlotLightbox');

            if (thumbnail) {
                thumbnail.onclick = function(){
                    lightbox.style.display = "block";
                    lightboxImg.src = this.src; 
                    lightboxCaption.innerHTML = this.alt;
                }
            }

            if (closeBtn) {
                closeBtn.onclick = function() {
                    lightbox.style.display = "none";
                }
            }
            if (lightbox) {
                lightbox.onclick = function(event) {
                    if (event.target === lightbox) { 
                        lightbox.style.display = "none";
                    }
                }
            }
        });

        function drawCd5DlbclResponseChart(containerId, legendContainerId) {
            const chartTitle = "CRR: Pola-R-CHP vs R-CHOP";
            const chartData = [
                { group: "Pola-R-CHP (N=27)", C3_CRR: 77.8, EOT_CRR: 77.8 },
                { group: "R-CHOP (N=56/55)", C3_CRR: 55.4, EOT_CRR: 69.1 }
            ];
            const subgroups = ["C3_CRR", "EOT_CRR"];
            const displayLabels = { "C3_CRR": "CRR at C3", "EOT_CRR": "CRR at EOT" };
            const p_values = { C3_CRR: "NS", EOT_CRR: "NS" }; // Abstract indicates no significant differences

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);
            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 450;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 350);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 50, right: 20, bottom: 70, left: 60 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g").attr("transform", \`translate(\${margin.left},\${margin.top})\`);
            const groups = chartData.map(d => d.group);
            
            const xScaleGroups = d3.scaleBand().domain(groups).range([0, chartWidth]).padding(0.4);
            const xScaleSubgroups = d3.scaleBand().domain(subgroups).range([0, xScaleGroups.bandwidth()]).padding(0.1);
            const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]);

            const color = d3.scaleOrdinal().domain(subgroups).range(["var(--sobi-teal)", "var(--sobi-orange)"]); // C3 CRR (Teal), EOT CRR (Orange)

            g.append("g").attr("transform", \`translate(0,\${chartHeight})\`).call(d3.axisBottom(xScaleGroups))
                .selectAll("text").attr("class", "axis-text").style("font-size", "9px").attr("transform", "rotate(-10) translate(-5,0)").style("text-anchor", "end");
            
            g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
            
            g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 15).attr("x", 0 - (chartHeight / 2))
                .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Complete Response Rate (%)");

            g.append("g").attr("class", "grid").call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
                .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

            const groupBars = g.selectAll(".group-bar").data(chartData).enter().append("g")
                .attr("class", "group-bar").attr("transform", d => \`translate(\${xScaleGroups(d.group)},0)\`);

            groupBars.selectAll("rect")
                .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
                .enter().append("rect")
                .attr("x", d => xScaleSubgroups(d.key)).attr("y", d => yScale(d.value))
                .attr("width", xScaleSubgroups.bandwidth()).attr("height", d => chartHeight - yScale(d.value))
                .attr("fill", d => color(d.key)).attr("rx", 2).attr("ry", 2);

            groupBars.selectAll(".bar-label")
                .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScaleSubgroups(d.key) + xScaleSubgroups.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 4).attr("text-anchor", "middle")
                .style("font-size", "9px").style("fill", "var(--sobi-dark-text)")
                .text(d => \`\${d.value.toFixed(1)}%\`);
            
            svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2)
                .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)").text(chartTitle);

            const pValueText = "P-values for C3 CRR and EOT CRR were not significant (p=0.3 reported for C4 CR in abstract, implies general non-significance)."
             g.append("text")
                .attr("x", chartWidth / 2)
                .attr("y", chartHeight + 35) 
                .attr("text-anchor", "middle")
                .attr("class", "axis-text")
                .style("font-size", "9px")
                .style("fill", "var(--sobi-dark-text)")
                .text(pValueText);

            const legendData = subgroups.map(key => ({ label: displayLabels[key], color: color(key) }));
            const legendItems = legendContainer.selectAll(".legend-item").data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawCD5DlbclChart = debounce(() => drawCd5DlbclResponseChart("#cd5DlbclResponseChart", "#cd5DlbclResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawCD5DlbclChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawCD5DlbclChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawCD5DlbclChart, 0); 
        }
    </script>
</body>
</html>